The sale of remaining rights to Allogene ends acrimony between the two companies.

The end of three licensed assets sees Takeda take a step back from autologous cell therapy.

Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.

The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.

Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.